Loading...
Loading...
In a research report published Wednesday, Morgan Stanley analyst Bin Li upgraded Sinovac Biotech Ltd.
SVA to Equal-Weight and raised the price target from $1.40 to $3.40.
In the report, Morgan Stanley noted, "Positive results of EV71 clinical studies and lower R&D costs lead us to raise our 2013-14 estimates. SVA may not turn profitable until 2015 – but earnings visibility is clearly better, and risk-reward now looks balanced."
Sinovac closed Tuesday at $3.33 and is currently trading down 0.30% since market open hours.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in